Product Information
Registration Status: ActiveANSTO - Sodium Iodide [131I] Therapy Capsules (50 to 6000 MBq) is approved to be sold in Singapore with effective from 2021-03-08. It is marketed by TRANSMEDIC PTE LTD, with the registration number of SIN16117P.
This product contains Sodium Iodide 50 to 6000 MBq/capsule in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by ANSTO in AUSTRALIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.
Indication
Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [L2065].
Pharmacokinetics
- Absorption
- Iodide salts are readily absorbed in the gastrointestinal tract [L2061].
- Distribution
- Iodides are distributed widely throughout extracellular fluid of thyroid gland [L2061].
- Metabolism
- Elimination
Toxicity
Acute oral LD50 is 4340 mg/kg in rat and 1000 mg/kg in mouse [MSDS]. Chronic iodide overdoses may result in iodism, which is commonly characterized by salivation, coryza, sneezing, conjunctivitis, headache, fever, laryngitis, bronchitis, stomatitis, parotitis and oedema of the glottis [L2061]. Up to 10g of sodium iodide has been administered intravenously without any signs of toxicity [L2061].
Active Ingredient/Synonyms
Sodium iodide | Sodium iodide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.